HRAS Q61K

CI-VAR-00003568Explore in graph →CIViC 1392

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Neoplasm2
HRAS Q61K AND BRAF G466E	Cetuximab	Predictive	D	Does Not Support Sensitivity Response	3	submitted	EID12447 Several BRAF mutant cell lines were analyzed in response to treatment with increasing concentrations of cetuximab (0-300nM). Cell-growth and impact on signalling was measured: ERK signalling by wester… (full text at CIViC) PMID 28783719 · Yao et al., 2017 · Open in CIViC	civic
HRAS Q61K AND BRAF G466E	Trametinib	Predictive	D	Supports Sensitivity Response	3	submitted	EID12454 Cell lines were treated with varying concentrations of trametinib for 3 days. Viability was measured by ATP-Glo. The melanoma cell line, SK-MEL-208 (BRAF G466E + HRAS Q61K), was sensitive with a low I… (full text at CIViC) PMID 28783719 · Yao et al., 2017 · Open in CIViC

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Skin Squamous Cell Carcinoma1
HRAS Q61K	Vemurafenib	Predictive	C	Supports Resistance	—	submitted	EID3850 In a retrospective study of 23 patients with BRAF V600 mutation (a known vemurafenib sensitizing mutation) that developed cutaneous squamous-cell carcinoma upon treatment with vemurafenib monotherapy,… (full text at CIViC) PMID 22256804 · Su et al., 2012 · Open in CIViC	civic